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Interleukin-1 inhibits PDGF-BBinduced
migration by cooperating with PDGF-BB to
induce cyclooxygenase-2 expression in baboon
aortic smooth muscle cells
Michael J. Englesbe, MD, Jessie Deou, AS, Brenda D. Bourns, PhD, Alexander W. Clowes, MD, and
Gu¨nter Daum, PhD, Seattle, Wash
Objective: Smooth muscle cell (SMC) migration from the media into the intima is pivotal for intimal formation after
vascular injury. Platelet-derived growth factor (PDGF)-BB is a potent chemoattractant for SMCs in vitro and in vivo. We
investigated whether interleukin (IL)–1 affects migration in response to PDGF-BB. Our data suggest that IL-1 is
inhibitory and that this effect is mediated by cyclooxygenase (COX)–2. We further addressed the role of the mitogen-
activated protein kinase p38, which is activated by PDGF-BB and by IL-1.
Methods: Baboon aortic SMCs were prepared with the explant method. Migration was measured in a Boyden chamber
assay through filters coated with monomeric collagen. COX2 expression and phosphorylation of p38 MAPK were
analyzed by Western blotting.
Results: PDGF-BB (10 ng/mL) stimulates migration 3.8-fold, and IL-1 (0.1 ng/mL) reduces this response by 40%. The
inhibitory effect of IL-1 is abolished by the COX inhibitor, indomethacin (10 mol/L), the specific COX2 inhibitor,
NS398 (10 mol/L), and the p38 MAPK inhibitor SB203580 (3 mol/L). We found that IL-1 and PDGF-BB
synergize to stimulate COX2 expression. We further demonstrated that p38 MAPK is activated by IL-1 and PDGF with
different kinetics and that p38 MAPK is required for maximal COX2 expression in response to IL-1 plus PDGF-BB.
Conclusion: IL-1 inhibits PDGF-BB–induced migration by cooperating with PDGF-BB to induce COX2 through
activation of p38 MAPK. Whether this effect of IL-1 modulates intimal growth after vascular injury remains to be
elucidated. (J Vasc Surg 2004;39:1091-6.)
Clinical Relevance: Restenosis is the cause of the unacceptably high failure rate of surgical interventions (such as vein
grafts, stents, and angioplasty) to restore blood flow in occluded vessels. It is clear that inflammatory processes are critical
for the development and progression of atherosclerotic lesions, and there is increasing evidence that inflammation also
contributes to restenosis. Recent observations that IL-1 receptors, agonists, and antagonists are expressed upon arterial
injury in various animal models strongly indicate a role for IL-1 in restenosis. This study investigates the effects of IL-1
on SMC migration, which is critical for the formation of an occluding intima. Our results suggest that IL-1 may limit the
accumulation of intimal cells after injury by blocking SMC migration in a mechanism that depends on expression of
cyclooxygenase-2.Recurrent stenosis is a serious complication of arterial
repair, and is caused by pathologic vessel remodeling and
intimal hyperplasia. Platelet deposition and degranulation
after arterial injury is a crucial process for neointimal
growth,1 and platelet-derived growth factor (PDGF) is the
major platelet-derived chemoattractant and mitogen for
smooth muscle cells (SMCs). The importance of PDGF in
intimal growth has been demonstrated in various animal
models, including baboons.2,3 The principal effect of
PDGF appears to be stimulation of SMC migration,2-6
although stimulation of SMC proliferation has also been
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doi:10.1016/j.jvs.2004.01.041suggested.7,8 PDGF effects in the response to vascular
injury appear to be mainly mediated by PDGF receptor
beta. For example, blockade of PDGF-receptor beta, but
not alpha, inhibits intimal hyperplasia in the balloon-in-
jured baboon carotid artery.2
There are multiple lines of evidence that inflammatory
processes contribute to recurrent stenosis after vascular
injury.9 Proinflammatory cytokines such as interleukin
(IL)–1 are potentially attractive targets to suppress intimal
hyperplasia, because they are unlikely to control normal
vessel functions. A role for IL-1 in recurrent stenosis has
been proposed.10 In human beings a polymorphism in the
IL receptor antagonist (IL-RA) locus has been discovered,
which may protect from recurrent stenosis after coronary
angioplasty11 and after coronary stenting.12 Although the
consequences of this polymorphism for IL-RA expression
in the vessel wall are not known, observations in IL-RA–
deficient mice point to an anti-inflammatory function of
IL-RA in arteries.13 Animal models in which IL-1 has been
investigated include pigs and mice. Chronic stimulation of1091
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lesions.14 In IL-1R1–deficient mice, compared with wild-
type animals, intimal hyperplasia is reduced after carotid
artery ligation.15 After balloon injury, expression of IL-1 is
induced in the rat carotid artery16 and pig coronary ar-
tery.17 Multiple mechanisms may contribute to stimulation
of intimal hyperplasia by IL-1, including direct activation of
SMC proliferation.
Because PDGF and IL-1 are generated concomitantly
at vascular injury, we investigated whether both factors
cooperate to stimulate SMC functions. We recently re-
ported that IL-1 potentiates PDGF-BB–induced prolifer-
ation. A likely mechanism is that IL-1 suppresses induc-
tion of cell cycle inhibitors p21 (WAF1/CIP1) and p27
(KIP1), thereby enhancing cyclin-dependent kinase 2 acti-
vation and proliferation.18
Here we investigated the effects of IL-1 on PDGF-
BB–induced migration. We found that IL-1 is inhibitory
and that this effect relies on synergistic expression of cyclo-
oxygenase (COX)–2 by IL-1 and PDGF-BB.
METHODS
Material. IL-1 was obtained from R & D Systems
(Minneapolis, Minn). PDGF-BB was generously provided
by Zymogenetics (Seattle, Wash). Indomethacin, NS398,
and SB203580 were purchased from Calbiochem (La Jolla,
Calif). Antibodies against COX2 and phospho-p38 MAPK
were from Cayman (Ann Arbor, Mich) and Cell Signaling
Technology (Beverly, Mass), respectively. All tissue culture
solutions were from Gibco/Invitrogen Life Technologies
(Carlsbad, Calif).
Cell culture. Baboon and human aortic SMCs were
prepared with the explant method.19 Aortic SMCs from
FVB mice were a kind gift from Michael Reidy (University
of Washington, Seattle). All cells were grown in Dulbecco
modified Eagle medium high glucose supplemented with
10% fetal bovine serum, 200 U/mL of penicillin, and 0.2
mg/mL of streptomycin. SMCs between 5 and 12 passages
were used. To achieve quiescence, growth medium was
removed and cells were incubated for 1 to 3 days in
MCDB131 supplemented with antibiotics and 2 mmol/L
of glutamine.
Western blot analysis. Quiescent SMCs were stimu-
lated with 10 ng/mL of PDGF-BB with or without 0.1
ng/mL of IL-1. Where indicated, SB203580 was added
30 minutes before stimulation. At the time points indi-
cated, cells were washed twice in phosphate-buffered saline
solution and lysed in Laemmli buffer containing 2% sodium
dodecylsulfate. Lysates were boiled, and subjected to so-
dium dodecylsulfate polyacrylamide gel electrophoresis
(10-30 g of protein per lane) followed by Western blot-
ting. Blots were blocked with 5% skim milk in Tris–Tween-
buffered saline solution (25 mmol/L of Tris hydrochloride
[pH 7.5], 150 mmol/L of sodium chloride, 0.1% Tween-
20) for 1 hour at room temperature, and incubated at 4°C
overnight with primary antibody (0.1-0.5 g/mL). Pro-
tein bands were visualized with enhanced chemilumines-
cence, according to the manufacturer’s protocol (Amer-sham/Pharmacia, Piscataway, NJ). For semiquantitative
analysis, films were scanned and band intensity was deter-
mined with Image Quant software (Molecular
Dynamics/Amersham).
Boyden chamber assay. Boyden chamber assays were
performed in a 48-well microchemotaxis chamber (Neuro
Probe, Gaithersburg, Md) with vitrogen-coated (Collagen
Corp, Palo Alto, Calif) polycarbonate filters (pore size, 10
m; Neuropore Corp, Pleasanton, Calif), as described.20
In brief, SMCs were grown in 10% fetal bovine serum to
near confluency, harvested, and counted. Cells (35,000 per
well) were placed in the upper chamber, and the lower
chamber contained the chemoattractant. Where indicated,
IL-1 was added to cells 2 hours before harvest. Inhibitors
were added 30 minutes before IL-1. Inhibitors and IL-1
were then added back into the upper chamber. The cham-
ber was kept for 5 hours at 37°C in a humidified incubator
at 5% carbon dioxide. Cells on the bottom of the filters were
fixed with methanol and stained with Diff-Quick staining
solution (Baxter, Deerfield, Ill). Migration was measured as
the number of cells per high-power field (100) that
migrated across the membrane between the upper and
lower chambers.
Statistical analysis. All experiments were performed
at least three times. Where indicated, statistical significance
between control and experimental groups was calculated
with adjusted Bonferroni comparisons21 or paired Student
t test. Differences at P  .05 were considered significant.
RESULTS
IL-1 inhibits PDGF-BB–induced migration in a
COX2 and p38 mitogen-activated protein kinase
(MAPK)–dependent manner. In a Boyden chamber as-
say, PDGF-BB (10 ng/mL) typically stimulates SMC mi-
gration by three to four times. This response is inhibited by
40% when IL-1 (0.1 ng/mL) is added (Fig 1). Doses of
PDGF-BB and IL-1 used have been recently established
as optimal in these cells for IL-1 and PDGF-BB with
respect to growth stimulatory effects of IL-1 on PDGF-
BB–induced proliferation.18 To test the possibility that
COX2 mediates the inhibitory effect of IL-1, we used the
general COX inhibitor indomethacin (10mol/L) and the
COX2 specific inhibitor NS398 (10 mol/L). Given pre-
vious observations that p38 MAPK is critical for COX2
expression by IL-1 in airway SMCs,22 we also investigated
the effect of the p38 MAPK inhibitor SB203580 (3-10
mol/L). Indomethacin (Fig 1, A) and SB203580 (Fig 1,
C) have no effect on PDGF-BB–induced migration,
whereas NS398 may be slightly inhibitory (Fig 1, B). The
migratory response to PDGF-BB in the presence of either
compound (indomethacin, NS-398, SB203580) was
higher than the response to PDGF-BB in the presence of
IL-1 (Fig 1). Addition of either drug significantly stimu-
lates migration by IL-1 plus PDGF-BB (Fig 1). Together
these data indicate thet IL-1 inhibits PDGF-BB–induced
migration in a mechanism that depends on COX2 and p38
MAPK.
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COX2 expression; role of p38 MAPK. To investigate
COX2 expression, we determined COX2 protein levels
with Western blotting after 5-hour stimulation with
PDGF-BB in the absence or presence of IL-1. The 5-hour
time point was chosen because Boyden chambers were also
incubated for 5 hours after PDGF-BB stimulation. IL-1
(0.1 ng/mL) alone induces COX2 expression twofold over
untreated controls, whereas PDGF-BB has no significant
effect. COX2 expression markedly increases in cells on
costimulation with IL-1 and PDGF-BB (Fig 2). Because
such synergism has not yet been reported, we addressed the
Fig 1. Interleukin-1 (IL-1) inhibits platelet-derived growth
factor-BB–induced migration in a mechanism dependent on cyclo-
oxygenase-2 and p38 mitogen-activated protein kinase. Where
indicated, smooth muscle cells were preincubated for 30 minutes
with 10 mol/L of indomethacin (A), 10 mol/L of NS398 (B),
or 3 mol/L of SB203589 (C) before addition of IL-1 (0.1
ng/mL) for 2 hours. Cells were harvested and subjected to Boyden
chamber assay with PDGF-BB (10 ng/mL) as stimulant (see
Methods). Data (mean  SD) are presented as percent activity,
with 100% for unstimulated controls (n  3 for each group).
Statistical significance for the indicated pairwise comparisons was
calculated with adjusted Bonferroni correction. All comparisons
are significant at P  .05.question of whether it is specific for baboon SMCs or is of
more general validity. We found synergistic expression of
COX2 by PDGF-BB and IL-1 in murine and human
SMCs (Fig 3).
To demonstrate that p38 MAPK is involved in COX2
expression by IL-1 and PDGF-BB, we measured COX2 in
SMCs treated with SB203580. The inhibitor blocks expres-
sion of COX2 under all conditions. Significant is an inhibi-
tion of 50% after stimulation with IL-1 plus PDGF-BB
(Fig 2). We next examined the extent to which IL-1 and
PDGF-BB contribute to p38 MAPK activation. Activity of
p38 MAPK was determined by assessing its phosphoryla-
tion status with a phospho-specific antibody. Both factors
transiently stimulate p38 MAPK, but the kinetics is differ-
ent. PDGF-BB activation of p38 MAPK peaks at 10 min-
utes, whereas p38 MAPK activation by IL-1 is maximal at
30 minutes (Fig 4). Costimulation of SMCs with IL-1
plus PDGF-BB results in higher p38 MAPK activity at each
time point when compared with cells stimulated with either
factor alone (Fig 4). After 60 minutes p38 MAPK phos-
phorylation is absent, regardless of stimulants used (Fig 4;
data for 3-hour, 4-hour, and 5-hour time points not
shown).
Fig 2. Platelet-derived growth factor-BB (PDGF-BB) and inter-
leukin-1 (IL-1) synergize to express cyclooxygenase-2 (COX2);
effect of SB203580. A, Quiescent baboon smooth muscle cells
were stimulated with 0.1 ng/mL of IL-1 and 10 ng/mL of
PDGF-BB in the absence (black bars) or presence (gray bars) of 10
mol/L of SB203580, as indicated. At 5 hours after stimulation,
protein was extracted and analyzed with Western blotting for
COX2 (see Methods). Data (mean SD) are presented as percent
COX2 expression, with 100% the strongest band per experiment.
In all four experiments, strongest COX2 expression was obtained
in response to IL-1beta plus PDGF-BB in the absence of
SB203580. A representative blot is included. *P  .008 (Student
t test).
essio
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Both IL-122-25 and PDGF26 have been described as
stimulating COX2 expression in SMCs. What has not yet
been appreciated is that both factors strongly cooperate to
induce COX2. This mechanism is present in human, ba-
Fig 3. Cyclooxygenase-2 (COX2) expression in murine
cells from mouse (black bars) and human being (gray bar
and platelet-derived growth factor-BB (PDGF-BB; 10 n
after stimulation. COX2 expression was analyzed after W
SD; n 4 for mouse, n 2 for human) are presented as
experiment. In all six experiments, strongest COX2 expr
Fig 4. Phosphorylation of p38 mitogen-activated prote
platelet-derived growth factor-BB (PDGF-BB). Quiesce
(IL, 0.1 ng/mL) and PDGF-BB (P, 10 ng/mL) for 10,
prepared and analyzed with Western blotting for phosph
 SEM, n  3) are presented as percent p38 MAPK pho
For all three experiments, p38 MAPK phosphorylation
minutes after stimulation.boon, and murine SMCs, whereas the potency of
PDGF-BB or IL-1 alone to stimulate COX2 expression
may vary between species (Figs 2 and 3). The reason for this
apparent difference between species is not known. One
major consequence of the synergistic expression of COX2
human smooth muscle cells. Quiescent smooth muscle
e stimulated with interleukin-1 (IL-1beta; 0.1 ng/mL)
), as indicated. Total cell lysates were prepared 5 hours
n blotting with densitometry of the films. Data (mean
nt COX2 expression, with 100% the strongest band per
n was obtained in response to IL-1 plus PDGF-BB.
ase (MAPK) in response to interleukin-1 (IL-1) and
boon smooth muscle cells were stimulated with IL-1
0, and 120 minutes, as indicated. Total cell lysates were
ted p38 MAPK. A, Representative blot. B, Data (mean
rylation, with 100% the strongest band per experiment.
strongest in response to IL-1 plus PDGF-BB at 30and
s) wer
g/mL
ester
percein kin
nt ba
30, 6
oryla
spho
was
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induced migration (Fig 1). The molecular basis for the
synergism between PDGF-BB and IL-1 in expressing
COX2 remains to be elucidated. Our data suggest that p38
MAPK, which is activated by both factors, with differing
kinetics (Fig 4), has a crucial role in maximal COX2 expres-
sion in response to IL-1 plus PDGF-BB. Blockade of p38
MAPK decreases COX2 expression to an extent that the
enzyme no longer inhibits PDGF-BB–induced migration
(Figs 1,C and 2). Given recent findings in other cell
types,27-29 it is likely that p38 MAPK is required for mes-
sage stabilization. Blockade of p38 MAPK does not abolish
COX2 expression by PDGF-BB plus IL-1, suggesting
additional cooperation of the two factors at the transcrip-
tion level. Our observation that PDGF-BB and IL-1
stimulate p38 MAPK with different kinetics may indicate
that both factors use different signaling pathways for p38
MAPK activation.
The role of COX2 in recurrent stenosis remains to be
clarified. COX2 is expressed at arterial injury, but blockade
of COX2 in the balloon-injured rat carotid artery had no
effect on lesion development.30 It is likely that conse-
quences of COX2 expression in the developing intima are
complex, and have positive and negative influence on neo-
intimal formation. COX2-mediated synthesis of inflamma-
tory prostaglandins may promote intimal growth by stim-
ulating recruitment of macrophages, which in turn release
SMC mitogens and chemoattractants. In addition, prosta-
glandins may stimulate the growth of new blood vessels,
which supply the growing intima. On the other hand,
prostaglandin E2 and prostacyclin both stimulate cyclic
adenosine monophosphate production in SMCs, which
inhibits proliferation. Consistent with this mechanism are
recent observations in prostacyclin receptor–deficient
mice, in which injury-induced vascular proliferation and
platelet activation are enhanced, compared with in con-
trols.31
Our observation that IL-1 inhibits SMC migration
suggests that IL-1 may attenuate intimal formation at
early stages after injury. We have recently reported that
IL-1 potentiates PDGF-BB–induced growth by inhibit-
ing expression of cell cycle–dependent kinase inhibitors
p21 and p27. It may be speculated that the immediate
release of IL-1 after injury restricts intimal formation by
inhibiting SMC migration, but when present over the long
term IL-1 promotes intimal growth by stimulation of
intimal SMC proliferation.
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